** Drugmaker Amneal Pharmaceuticals' AMRX.O shares rise 1.4% to $8.5 premarket
** Co forecasts 2025 revenue in the range of $3.0 bln to $3.1 bln, higher than analysts' estimate of $2.9 bln, as per data compiled by LSEG
** AMRX posts Q4 revenue of $731 mln vs analysts' estimate of $707.6 mln
** Co reports Q4 adj profit of 12 cents/share vs analysts' estimates of 15 cents/share
** AMRX expects 2025 adj profit in the range of 65 cents/share to 70 cents/share, analysts on average expect 2025 adj profit of 73 cents/share
** Stock has risen 46.8% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.